Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Gail J. Roboz, MD, Farhad Ravandi, MBBS, Andrew H Wei, MBBS, PhD, Hervé Dombret, MD, Hartmut Döhner, Felicitas Thol, Maria Teresa Voso, MD, Andre C. Schuh, Kimmo Porkka, Ignazia La Torre, Barry Skikne, MD, Keshava Kumar, PhD, Qian Dong, DrPH, C.L. Beach, PharmD, Alberto Risueño, Daniel Lopes de Menezes, PhD, Gert Ossenkoppele, MD PhD

Blood (2020) 136 (Supplement 1): 32–33.

https://doi.org/10.1182/blood-2020-140837

Published: 2020

Journal Articles

Lenalidomide with or without Erythropoietin and Granulocyte-Colony Stimulating Factor Shows Efficacy in Patients with Low and Intermediate-1 Risk Myelodysplastic Syndrome with or without Del 5q, Refractory or Unlikely to Respond to Erythropoietin. Results of a HOVON89 Phase II Randomized Multicenter Study. (EudraCT 2008-002195-10)

Blood (2016) 128 (22): 224.

https://doi.org/10.1182/blood.V128.22.224.224

Published: 2016

Journal Articles

Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT)

Jan J. Cornelissen, MD PhD, Yvette van Norden, MD PhD MSc., Michel van Gelder, MD PhD, Dimitri A. Breems, MD PhD, Johan Maertens, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Annoek Broers, MD PhD, Sacha S. Zeerleder, MD PhD, Lucien Noens, MD PhD, Gert Ossenkoppele, MD PhD, Ellen Meijer, MD PhD

Blood (2016) 128 (22): 832.

https://doi.org/10.1182/blood.V128.22.832.832

Published: 2016

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Blood (2011) 118 (21): 159.

https://doi.org/10.1182/blood.V118.21.159.159

Published: 2011

Journal Articles

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Alida C. Weidenaar, Arja ter Elst, PhD, Cees AGM van Montfort, PhD, Tiny G.J. Meeuwsen-de Boer, Stefano Rosati, MD, Mario Bargetzi, MD, Carlos Graux, MD, PhD, Alois Gratwohl, MD, PhD, Bob Lowenberg, MD, PhD, Gert Ossenkoppele, MD, PhD, Evelina S. De Bont, MD, PhD

Blood (2011) 118 (21): 1555.

https://doi.org/10.1182/blood.V118.21.1555.1555

Published: 2011

Journal Articles

Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry

Blood (2011) 118 (21): 1688.

https://doi.org/10.1182/blood.V118.21.1688.1688

Published: 2011

Journal Articles

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

David Marin, Enrica Morra, MD, Mauricette Michallet, Andrzej Hellmann, MD, Dietger Niederwieser, MD, Ernst Schloegl, MD, Mats Björeman, MD, Kajetana Foryciarz, MD, PhD, Aloysius Y Ho, Kazimierz Kuliczkowski, Gert Ossenkoppele, MD, PhD, Antonella Gozzini, MD, M. Lurdes Guerra, MD, Gregor Verhoef, Ave Mori, MD, Miranda Pans, Marc van Baardewijk, Pharm.D, Juan Luis Steegmann, MD, PhD

Blood (2011) 118 (21): 1689.

https://doi.org/10.1182/blood.V118.21.1689.1689

Published: 2011

Journal Articles

hsTRAIL/Apo2L Induces Apoptosis in Enteropathy-Associated T-Cell Lymphoma

Marijn Radersma, MD, Laura R de Baaij, MD, Nathalie J Hijmering, Gert Ossenkoppele, MD, PhD, Chris JLM Meijer, MD, PhD, Chris JJ Mulder, MD, PhD, Saskia AGM Cillessen, PhD

Blood (2011) 118 (21): 1665.

https://doi.org/10.1182/blood.V118.21.1665.1665

Published: 2011

Journal Articles

90 yttrium Ibritumomab Tiuxetan-BEAM Followed by Autologous Stem Cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction Therapy in Patients with High-Risk Aggressive B Cell Non-Hodgkin's Lymphoma

Marielle Wondergem, MD, Madelon de Rooij, MD, Josee Zijlstra, Otto J Visser, MD, Gert Ossenkoppele, MD, PhD, Peter C. Huijgens, MD, PhD

Blood (2011) 118 (21): 3078.

https://doi.org/10.1182/blood.V118.21.3078.3078

Published: 2011

Journal Articles

Treatment with Lenalidomide in Myelodysplastic Syndromes with 5q Deletion; Results From the Patient Named Program (PNP) in the Netherlands

Imane Abouyahya, Canan Alhan, MD, Theresia M Westers, PhD, Jan Koedam, Gert Ossenkoppele, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD

Blood (2011) 118 (21): 5032.

https://doi.org/10.1182/blood.V118.21.5032.5032

Published: 2011

Journal Articles

Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia

Noortje Thielen, Bronno van der Holt, Jan J Cornelissen, MD PhD, Rianne Ammerlaan, Pieter Sonneveld, MD, PhD, Marie José Kersten, J.H. Frederik Falkenburg, Harm Sinnige, Martin Schipperus, Anton Schattenberg, Marinus van Marwijk Kooy, Willem Smit, Gregor Verhoef, Isabel Chu, Peter Valk, Jeroen JWM Janssen, MD PhD, Gert Ossenkoppele, MD, PhD

Blood (2011) 118 (21): 2758.

https://doi.org/10.1182/blood.V118.21.2758.2758

Published: 2011

Journal Articles

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Francis J. Giles, MB, MD, FRCPI, FRCPath, Gianantonio Rosti, MD, Gert Ossenkoppele, MD, PhD, Michel Tulliez, Jesper Stentoft, MD, PhD, Aristoteles Giagounidis, MD, Francesco Nobile, MD, Philipp D. le Coutre, MD, Norbert Gattermann, MD, Laimonas Griskevicius, Nicholas C.P. Cross, PhD, FRCPath, Sarah Hill, BSc (hons), PhD, MICR, Peter Schuld, PhD, Angela Pellegrino, Domenico Magazzù, Andreas Hochhaus, MD

Blood (2011) 118 (21): 2759.

https://doi.org/10.1182/blood.V118.21.2759.2759

Published: 2011

Journal Articles

Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML

Dietger Niederwieser, MD, Leo F Verdonck, Jan J Cornelissen, MD PhD, Michael Cross, PhD, Rainer Krahl, MD, Thoralf Lange, Vladan Vucinic, Georg Franke, MD, Haifa K. Al-Ali, MD, Gert Ossenkoppele, MD, PhD, Georg Maschmeyer, MD, Gottfried Doelken, MD, Mathias Freund, MD, Norma Peter, Marc Boogaerts, MD, PhD, Alois Gratwohl, MD, Harry C. Schouten, MD, PhD, Bob Lowenberg, MD, PhD

Blood (2011) 118 (21): 2030.

https://doi.org/10.1182/blood.V118.21.2030.2030

Published: 2011

Journal Articles

Results From the ENESTnd Extension Study: Efficacy and Safety of Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP), Treated with Nilotinib 400 Mg Twice Daily (BID) After Suboptimal Response (SoR) or Treatment Failure (TF) to Imatinib 400 Mg Once Daily (QD) or Nilotinib 300 Mg BID

Andreas Hochhaus, MD, Gert Ossenkoppele, MD, PhD, Josy Reiffers, MD, Ming Yao, MD, Hirohiko Shibayama, MD, PhD, Norbert Gattermann, MD, Timothy P. Hughes, MD, MBBS, Giuseppe Saglio, MD, Richard A. Larson, MD, Albert Hoenekopp, MD, Neil J. Gallagher, MD, PhD, Richard Yu, Rick E. Blakesley, PhD, Clarisse Lobo, MD, Hagop M. Kantarjian

Blood (2011) 118 (21): 114.

https://doi.org/10.1182/blood.V118.21.114.114

Published: 2011

Journal Articles

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

Gert Ossenkoppele, MD, PhD, Bob Lowenberg, MD, PhD, Pierre Zachee, MD, PhD, Norbert Vey, Dimitri Breems, MD, PhD, Arjan A. Van de Loosdrecht, MD, PhD, Phillip Debnam, PhD, Lindsey Needham, PhD, Lindsay Bawden, PhD, Leon Hooftman, MD

Blood (2010) 116 (21): 3279.

https://doi.org/10.1182/blood.V116.21.3279.3279

Published: 2010

Journal Articles

The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved

Gerrit J. Schuurhuis, PhD, Angèle Kelder, Monique Terwijn, Arjo P Rutten, Linda Smit, PhD, Sonja Zweegman, MD, PhD, Gert Ossenkoppele, MD, PhD

Blood (2010) 116 (21): 2725.

https://doi.org/10.1182/blood.V116.21.2725.2725

Published: 2010

Journal Articles

Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter.

Monique Terwijn, Angèle Kelder, Arjo P Rutten, Alexander N Snel, Willemijn Scholten, Sonja Zweegman, MD, PhD, Gert Ossenkoppele, MD, PhD, Gerrit Jan Schuurhuis, PhD

Blood (2009) 114 (22): 399.

https://doi.org/10.1182/blood.V114.22.399.399

Published: 2009

Journal Articles

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.

Wendy Deenik, MD, Bronno van der Holt, PhD, Jeroen JWM Janssen, MD, Isabel W.T. Chu, Peter Valk, PhD, Gert Ossenkoppele, MD, PhD, Ilse van der Heiden, Pieter Sonneveld, MD, PhD, Ron van Schaik, PhD, Jan J. Cornelissen, MD, PhD

Blood (2009) 114 (22): 2208.

https://doi.org/10.1182/blood.V114.22.2208.2208

Published: 2009

Journal Articles

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Philipp D. le Coutre, MD, Francis Giles, MD, Andreas Hochhaus, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, Gert Ossenkoppele, MD, PhD, Ariful Haque, Neil J. Gallagher, MD, PhD, Michele Baccarani, MD, Jorge Cortes, MD, Hagop M Kantarjian

Blood (2008) 112 (11): 3229.

https://doi.org/10.1182/blood.V112.11.3229.3229

Published: 2008

Journal Articles

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Jorge Cortes, MD, Elias Jabbour, MD, Andreas Hochhaus, MD, Philipp le Coutre, MD, Michele Baccarani, MD, Kapil N. Bhalla, MD, Gert Ossenkoppele, MD, PhD, Norbert Gattermann, MD, PhD, Ariful Haque, Neil Gallagher, Francis Giles, MD, Hagop M. Kantarjian, MD

Blood (2007) 110 (11): 1040.

https://doi.org/10.1182/blood.V110.11.1040.1040

Published: 2007

NARROW

CC-486 Prolongs Survival for Patients with Acute Myeloid Leukemia (AML) in Remission after Intensive Chemotherapy (IC) Independent of the Presence of Measurable Residual Disease (MRD) at Study Entry: Results from the QUAZAR AML-001 Maintenance Trial

Early Post-Transplant Epigenetic Therapy By Panobinostat and Decitabine Followed By Donor Lymphocyte Infusion (DLI): Interim Results of the HOVON-116 Phase I/II Feasibility Study in Poor-Risk AML Recipients of Allogeneic Stem Cell Transplantation (alloHSCT)

Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Improves Outcome As Compared to Conventional Consolidation in Patients Aged 40–60 Years with AML in CR1 with Apparent Greater Benefit for Reduced Intensity Rather Than Myeloablative Conditioning

Patterns of Bone Marrow Micro Vessel Morphology in AML and High Risk MDS Predict Treatment Outcome Following Intensive Chemotherapy and Bevacizumab

Outcome of Patients with Chronic Myeloid Leukemia After Allogeneic Stem Cell Transplantation in Europe; Data From the EUTOS for CML Registry

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

hsTRAIL/Apo2L Induces Apoptosis in Enteropathy-Associated T-Cell Lymphoma

90 yttrium Ibritumomab Tiuxetan-BEAM Followed by Autologous Stem Cell Transplantation Significantly Improves Overall Survival After Rituximab Containing Induction Therapy in Patients with High-Risk Aggressive B Cell Non-Hodgkin's Lymphoma

Treatment with Lenalidomide in Myelodysplastic Syndromes with 5q Deletion; Results From the Patient Named Program (PNP) in the Netherlands

Preliminary Results From a Phase III Trial of Imatinib Versus Imatinib in Combination with Cytarabine in Patients with First Chronic Phase Myeloid Leukemia

A Phase IIIb Multicentre Open-Label Study of Nilotinib in Adult Patients with Newly Diagnosed BCR-ABL Positive Chronic Myeloid Leukemia (CML) in Chronic Phase (CP): A European Clinical Initiative with EUTOS Collaboration for Standardisation of Molecular Remission

Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML

CHR-2845, a Monocyte/Macrophage Targeted Histone Deacetylase Inhibitor In a First In Man Clinical Trial In Subjects with Advanced Haematological Malignancies

The Prognostic Value of CD34 Expression In Acute Myeloid Leukemia. A Mystery Solved

Leukemic Stem Cell Assessment in Remission Bone Marrow of Acute Myeloid Leukemia Patients Is a New Prognostic Parameter.

Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.

Nilotinib in Chronic Myeloid Leukemia Patients in Accelerated Phase (CML-AP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study

Nilotinib Is Associated with Minimal Cross Intolerance to Imatinib in Patients with Imatinib-Intolerant Philadelphia-Positive (Ph+) Chronic Myelogenous Leukemia (CML) in Either Chronic Phase (CP) or Accelerated Phase (AP).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only